IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Starting in the 1980s, interferon (IFN)-α was the primary treatment for Chronic Myeloid Leukemia (CML), offering a reduction in disease burden and a modest improvement in survival compared to other treatments.